Caris Life Sciences (CAI) Total Current Liabilities (2024 - 2026)

Caris Life Sciences' Total Current Liabilities history runs 3 years deep, the most recent figure standing at $143.9 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities changed N/A year-over-year to $143.9 million in Q1 2026; TTM through Mar 2026 was $143.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $127.1 million, down 23.14% from the prior year.
• Total Current Liabilities improved to $143.9 million in Q1 2026 per CAI's latest filing, from $127.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $165.4 million in Q4 2024 and bottomed at $86.0 million in Q3 2025.
• The 3-year median for Total Current Liabilities is $127.1 million (2025), against an average of $122.5 million.
• Biggest YoY gain for Total Current Liabilities was 23.14% in 2025; the steepest drop was 23.14% in 2025.
• Year by year, Total Current Liabilities stood at $165.4 million in 2024, then decreased by 23.14% to $127.1 million in 2025, then advanced by 13.17% to $143.9 million in 2026.
• Per Business Quant, the three latest CAI Total Current Liabilities figures stand at $143.9 million (Q1 2026), $127.1 million (Q4 2025), and $86.0 million (Q3 2025).